Inceptive

Inceptive reports testing five model-generated anti-CD19 CAR mRNA designs in NSG-PBMC humanized mice using matched dosing and a 24-hour endpoint. Three designs reportedly exceeded the comparator in B-cell killing; the M4 figure uses four animals. This is company-reported preclinical scientific impact, not patient efficacy or commercial deployment.

Inceptive has strategic drug-design collaborations including a 2026 Alnylam RNAi alliance valued up to $2B, but broad commercial deployment remains earlier than mature global platforms.

Inceptive has strategic drug-design collaborations including a 2026 Alnylam RNAi alliance valued up to $2B, but broad commercial deployment remains earlier than mature global platforms.

Inceptive develops end-to-end biological foundation models for sequence-based medicines, combining heterogeneous biological data with rapid wet-lab validation.

Inceptive develops end-to-end biological foundation models for sequence-based medicines, combining heterogeneous biological data with rapid wet-lab validation.

Alnylam entered a strategic collaboration valued at up to $2B with Inceptive, explicitly pairing Alnylam RNAi data with Inceptive foundation models and AI expertise to accelerate novel oligonucleotide therapeutic design.

Inceptive reports a named collaboration with Mana.bio combining its de novo mRNA sequence designs with Mana.bio's LNP formulation platform in experimental CAR-T work. This adds a concrete cross-company execution example beyond generic drugmaker partnerships and office locations.

Inceptive combines frontier AI researchers, biochemists, wet-lab experimentation and drugmaker partnerships across Palo Alto, Berlin and Zurich.

Inceptive combines frontier AI researchers, biochemists, wet-lab experimentation and drugmaker partnerships across Palo Alto, Berlin and Zurich.

Inceptive describes models selecting informative experiments, automated high-throughput arrayed and pooled assays, and feeding resulting sequence-test data back into retraining after task-specific fine-tuning.

Foundation-model and ML research skills transfer broadly, while RNA therapeutics and experimental biology specialization limits full portability.

Foundation-model and ML research skills transfer broadly, while RNA therapeutics and experimental biology specialization limits full portability.